IP Library Granted Patent US 8,003,770
Granted Patent B2
US 8,003,770 · App. 11/991,964 · Granted Aug 23, 2011

T-cell receptor and nucleic acid encoding the receptor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,003,770
App. No.
11/991,964
Granted
Aug 23, 2011
Kind
B2
Abstract

A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4 143-151 -specific T cell receptor together with a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 2 of Sequence Listing.

Claims (22)

1. A recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 5.

2. The recombinant nucleic acid according to claim 1 , wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 6.

3. A recombinant nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 7.

4. The recombinant nucleic acid according to claim 3 , wherein the nucleic acid comprises the nucleotide sequence shown in SEQ ID NO: 8.

5. The recombinant nucleic acid according to claim 1 , wherein the nucleic acid encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 1.

6. The recombinant nucleic acid according to claim 2 , wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 3.

7. The recombinant nucleic acid according to claim 3 , wherein the nucleic acid encodes a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

8. The recombinant nucleic acid according to claim 4 , wherein the nucleic acid is a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 4.

9. The recombinant nucleic acid according to claim 1 , wherein the nucleic acid encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.

10. The recombinant nucleic acid according to claim 2 , wherein the nucleic acid consists of the nucleotide sequence of SEQ ID NO: 3 or SEQ ID NO: 6.

11. The recombinant nucleic acid according to claim 3 , wherein the nucleic acid encodes a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 7.

12. The recombinant nucleic acid according to claim 4 , wherein the nucleic acid is a nucleic acid consisting of the nucleotide sequence of SEQ ID NO: 4 or SEQ ID NO: 8.

13. A vector comprising the recombinant nucleic acid as defined in claim 1 or claim 5 , wherein the recombinant nucleic acid is inserted into the vector.

14. A vector selected from the group consisting of:

(1) a vector comprising a recombinant nucleic acid comprising the nucleic acid as defined in claim 1 or claim 5 , and a recombinant nucleic acid comprising the nucleic acid as defined in claim 3 or claim 7 , wherein both of the recombinant nucleic acids are inserted into the vector; and

(2) a combination of vectors comprising a recombinant nucleic acid comprising the nucleic acid as defined in claim 1 or claim 5 , wherein the recombinant nucleic acid is inserted into a first vector, and a second vector comprising a recombinant nucleic acid comprising the nucleic acid as defined in claim 3 or claim 7 , wherein the recombinant nucleic acid is inserted into the second vector.

15. A carcinostatic agent comprising an active ingredient selected from the group consisting of:

(1) a vector comprising the recombinant nucleic acid as defined in claim 1 or claim 5 , wherein the recombinant nucleic acid is inserted into the vector,

(2) a vector comprising the recombinant nucleic acid as defined in claim 3 or claim 7 , wherein the recombinant nucleic acid is inserted into the vector,

(3) a vector comprising a recombinant nucleic acid comprising the nucleic acid as defined in claim 1 or claim 5 , and a recombinant nucleic acid comprising the nucleic acid as defined in claim 3 or claim 7 , wherein both of the recombinant nucleic acids are inserted into the vector; and

(4) a combination of vectors comprising a recombinant nucleic acid comprising the nucleic acid as defined in claim 1 or claim 5 , wherein the recombinant nucleic acid is inserted into a first vector, and a second vector comprising a recombinant nucleic acid comprising the nucleic acid as defined in claim 3 or claim 7 , wherein the recombinant nucleic acid is inserted into the second vector.

16. A vector comprising the recombinant nucleic acid as defined in claim 3 or claim 7 .

Assignments (2)
CHANGE OF ADDRESS Recorded Jun 24, 2016
From: TAKARA BIO INC.
To: TAKARA BIO INC.
Reel/Frame 039152/0834 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2008
From: SHIKU, HIROSHI; HIASA, ATSUNORI; OKUMURA, SATOSHI; NAOTA, HIROAKI; MIYAHARA, YOSHIHIRO
To: MIE UNIVERSITY; TAKARA BIO INC.
Reel/Frame 021955/0744 →